As downstream bioprocessing improvements continue, efforts are underway to integrate downstream processes into continuous operations.

對於仍處於初創階段、尚未擁有商業化産品的中小規模創新型藥企而言，提高自主創新能力的同時，依靠整合并購實現升級轉型，逐漸向頭部靠攏，不失為未來獲得資本青睐的出路。

11月7日，在第三屆中國國際進口博覽會上，創勝集團與默克宣布戰略技術合作，共同推進治療性蛋白藥物的連續流生産。

繼日前Claudin18.2人源化單克隆抗體新藥TST001，獲美國食藥監局和中國藥監局針對轉移性實體瘤患者進行臨床試驗許可後，7月1日，創勝集團宣布在美國開展的I期臨床研究已完成首例患者給藥。

Transcenta, a privately-owned, US-China-based integrated biopharmaceutical company, is in the process of marching ahead with an initial public offering (IPO) after receiving a USD 100m Series B+ funding this January, according to company Chief Executive Ofcer Dr. Xueming Qian and Executive Chairman Dr. Jonathan Zhao. The two co-founders said that the company is in crossover funding talks with potential investors, and aims to kick off the Hong Kong IPO at the end of this year.

After announcing a $100 million Series B+ funding, the biotech company’s CEO tells FinanceAsia it is now in full IPO preparation mode with Hong Kong as its preferred destination. However, a dual listing is not out of the question.